

# Max Healthcare

Estimate change	↔
TP change	↓
Rating change	↔

Motilal Oswal values your support in the EXTEL POLL 2025 for India Research, Sales, Corporate Access and Trading team. We request your ballot.



Bloomberg	MAXHEALT IN
Equity Shares (m)	972
M.Cap.(INRb)/(USDb)	1090.5 / 12.3
52-Week Range (INR)	1314 / 936
1, 6, 12 Rel. Per (%)	-8/-8/1
12M Avg Val (INR M)	2950

## Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	106.3	125.9	140.0
EBITDA	28.0	33.5	37.4
Adj. PAT	17.6	22.9	25.1
EBIT Margin (%)	21.7	22.5	22.1
Cons. Adj. EPS (INR)	18.1	23.7	25.9
EPS Gr. (%)	19.6	30.7	9.6
BV/Sh. (INR)	125.8	147.5	173.4

## Ratios

Net D:E	0.1	0.0	(0.1)
RoE (%)	16.7	17.3	16.2
RoCE (%)	14.8	15.4	14.6
Payout (%)	10.4	8.5	0.0

## Valuations

P/E (x)	58.1	48.2	44.0
EV/EBITDA (x)	39.9	33.1	29.1
Div. Yield (%)	0.2	0.2	0.0
FCF Yield (%)	0.5	1.1	1.7
EV/Sales (x)	10.5	8.8	7.8

## Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	23.7	23.7	23.7
DII	20.0	17.4	15.1
FII	51.8	54.8	57.3
Others	4.4	4.1	3.8

FII Includes depository receipts

**CMP: INR1,122**      **TP: INR1,360 (+21%)**      **Buy**

## Steady delivery; bed capacity expansion continues

### Existing units deliver strong volume-led growth; expansion pipeline supports multi-year visibility

- Max Healthcare (MAXH) reported in-line revenue and slightly better-than-expected EBITDA in 2QFY26.
- The overall performance was robust, with consistent 20%+ YoY revenue growth and better or in-line EBITDA YoY growth. The bed addition on the brownfield basis is expected to help MAXH sustain the growth momentum going forward.
- For the existing units (network hospitals/facilities started before 3QFY25), revenue growth of 14.4% YoY was largely driven by patient volume, while EBITDA growth stood at 18.6% YoY. Pre-tax ROCE of the existing units is commendable at 26%.
- The scale-up of new units is also on track, with revenue/EBITDA growth of 8%/14% YoY in for the quarter.
- Free cash flow from operations (INR3b/INR7b) has been utilized for ongoing expansions and facility upgrades.
- We largely maintain our estimates for FY26/FY27/FY28. We continue to value MAXH on an SoTP basis (premised on 35x 12M forward EV/EBITDA for the hospital business, 30x 12M forward EV/EBITDA for Max@lab, and 11x EV/sales for Max@home) to arrive at our TP of INR1,360.
- MAXH continues to implement efforts for sustainable growth in revenue/EBITDA/PAT, supported by bed additions (1300 beds in FY26 and ~500 beds in FY27). In fact, the land bank available with MAXH would enable bed additions on the brownfield basis for the next 5-7 years. It continues to optimize case mix/payor mix to further improve profitability. Maintain BUY.

## Steady 2QFY26 with strong revenue and stable margins

- In 2Q, Max network revenue (including the trust business) grew 21.4% YoY to INR25.7b (our est. INR26.0b).
- EBITDA margin slightly contracted by 10bp YoY to 26.7% (our est. 25.4%).
- EBITDA grew 21.2% YoY to INR6.9b (our est. INR 6.6b).
- MAXH recorded a one-time gain of INR1.5b from the merger accounting of CRL and JHL (both WoS).
- Adjusting for this one-time gain, ETR would be 21%.
- Accordingly, adj. PAT would be INR4.3b (our est: INR4.4b).
- EBITDA per bed (annualized) stood at INR7.3m for the quarter. Excluding recently added beds, EBITDA per bed was INR7.6m, up 7.4% YoY.
- In 1HFY26, revenue/EBITDA/PAT grew 24%/23%/17% YoY to INR50.2b/INR13.0b/INR8.0b.

**Tushar Manudhane - Research Analyst** (Tushar.Manudhane@MotilalOswal.com)

**Vipul Mehta - Research Analyst** (Vipul.Mehta@MotilalOswal.com) **Eshita Jain - Research Analyst** (Eshita.Jain@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

### Highlights from the management commentary

- CGHS tariff revision is effective from 13th Oct and expected to contribute over INR2b in incremental annual revenue.
- Temporary insurance cashless disruption fully resolved, with future revision cycles pre-agreed.
- Brownfield expansions progressing: Mohali 160 beds commissioned; Nanavati 268 beds commissioning this week; Max Smart 400 beds within 30 days (EBITDA break-even expected immediately).
- International patient business grew 25% YoY, driven almost entirely by volumes.
- Large multi-city capacity pipeline active across Lucknow, Gurgaon, Nagpur, Patparganj, Saket, Mohali, Vaishali, Thane & Pitampura with timelines ranging 24–42 months.
- Lucknow: Expanding from 413 to 550 beds with onco-radiation/PET-CT launching in 2 weeks; completion by FY26-end.
- Mohali: 400-bed expansion ahead of schedule; expected by end-2027.
- Nagpur: 100-bed expansion awaiting CTE; to complete 24 months after approval.
- Vaishali: 140-bed project with demolition completed; 24-month duration post approvals.

### Consolidated - Quarterly Earning Model

Y/E March	FY25					FY26E				FY25	FY26E	FY26 % var
(INRm)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			2QE	
Gross Sales	19,310	21,190	22,690	23,020	24,510	25,720	27,339	28,779	86,210	1,06,347	25,992	-1.0
YoY Change (%)	19.1	23.3	34.9	28.5	26.9	21.4	20.5	25.0	26.5	23.4	34.6	
Total Expenditure	14,370	15,520	16,520	16,950	18,340	18,850	20,066	21,095	63,360	78,351	19,390	
EBITDA	4,940	5,670	6,170	6,070	6,170	6,870	7,272	7,684	22,850	27,996	6,602	4.1
Margins (%)	25.6	26.8	27.2	26.4	25.2	26.7	26.6	26.7	26.5	26.3	25.4	
Depreciation	900	970	1,060	1,140	1,170	1,220	1,244	1,310	4,070	4,944	1,043	
Interest	80	50	350	360	340	410	427	443	840	1,620	319	
Other Income	40	60	110	240	80	80	120	130	450	410	100	
PBT before EO expense	4,000	4,710	4,870	4,810	4,740	5,320	5,721	6,062	18,390	21,843	5,341	-0.4
Extra-Ord expense	190	270	1,000	180	330	180	0	0	1,640	510	0	
PBT	3,810	4,440	3,870	4,630	4,410	5,140	5,721	6,062	16,750	21,333	5,341	-3.8
Tax	870	950	710	870	960	-410	1,058	1,134	3,400	2,742	988	
Rate (%)	22.8	21.4	18.3	18.8	21.8	-8.0	18.5	18.7	20.3	12.9	18.5	
Minority Interest & Profit/Loss of Asso. Cos.	0	0	0	0	0	0	0	0	0	0	0	
Reported PAT	2,940	3,490	3,160	3,760	3,450	5,550	4,662	4,928	13,350	18,591	4,353	
Adj PAT	3,087	3,702	3,977	3,906	3,708	4,254	4,662	4,928	14,672	17,553	4,353	-2.3
YoY Change (%)	1.0	4.9	16.5	17.7	20.1	14.9	17.2	26.2	10.2	19.6	41.0	
Margins (%)	16.0	17.5	17.5	17.0	15.1	16.5	17.1	17.1	17.0	16.5	16.7	
EPS	3.2	3.8	4.1	4.0	3.8	4.4	4.8	5.1	15.1	19.6	4.5	-2.3

### Key operating updates

- For the hospital business, ARPOB stood at INR77.3k in 2QFY26 (+1.4% YoY). Excluding newly added beds, ARPOB was INR78.7k, up 3.3% YoY.
- Occupancy came in at 77% in 2QFY26 (vs. 79%/76% in 2QFY25/1QFY26), with Occupied bed days (OBDs) up by +19% YoY and +4% QoQ.
- The payor mix changed as the cash segment's revenue share increased 20bp YoY to 35.5%, the institutional revenue share increased 300bp YoY to 21.5%, the international revenue share increased 30bp YoY to 9.2%, and the TPA and Corporate segment's revenue share declined 350bp YoY to 33.8%.
- Max Lab's revenue was INR540m for 2QFY26 (+16% YoY).




- Max Home's gross revenue was INR630m (+20% YoY).
- International patient revenue was INR2.3b in 2QFY26 (up by +25% YoY).
- Free cash from operations was INR2.9b vs. INR4.6b in 2QFY25 and INR3.9b in 1QFY26.


### Other Conference Call Highlights

- Other projects in pipeline:
  - Patparganj: 397-bed project fully approved with barricading done; slated for FY28 completion.
  - Saket: 550-bed project to start after Max Smart commissioning; 40-month execution timeline.
  - Thane: 500-bed project with master plan finalized; 42-month completion cycle.
  - Pitampura: 250-bed project awaiting building plan approvals; 36-month build time thereafter.
  - Gurugram: 500-bed project progressing; minor delays in base work.
- Existing units ARPOB growth was 3% YoY. Over a period of time, the addition of institutional and insurance patients in hospitals dragged down ARPOB growth. However, this was more than offset by higher patient flow.
- Doctor attrition remained extremely low at 1-1.5%, with no material impact from recent departures.
- Capex in 2HFY26 is guided at ~INR11-12b, higher than 1H capex (INR9b).
- Merger of two subsidiaries approved, with a one-time INR1.5b tax benefit in 2Q.
- Completed divestment of Chitta & Anoopshahr hospitals, as per of corporate restructuring strategy.


**Exhibit 1: ARPOB stable YoY on an overall basis**



**Exhibit 2: Occupancy rate stood at 77% in 2QFY26**



**Exhibit 3: Operating EBITDA per bed down 2% YoY/up 7% QoQ in 2QFY26**



Source: MOFSL, Company

## Set for consistent growth over next 3-5 years

### Scales through brownfield, greenfield, M&A and built-to-suit models

- MAXH increased the number of operational beds by 21% YoY to 4,760 in 1H.
- Low ARPOB in certain new hospitals resulted in modest 1.3% YoY ARPOB growth; however, ARPOB at existing hospitals grew 3.1% YoY in 1H.
- Revenue grew 24% YoY in 1HFY26, supported by a 22% YoY rise in OBDs.
- International patient revenue increased 28% YoY in 1HFY26 and accounted for ~9% of hospital revenue, driven by higher volumes and targeted efforts across Eastern Europe, the Middle East, and Africa.
- In payor mix, institutional share was up 340bp YoY, while TPA and corporates share declined 320bp YoY during 1HFY26.
- EBITDA per bed (excluding new units) was INR7.1m in 1HFY26, up 4.3% YoY.
- MAXH invested INR8.9b in ongoing expansion and facility upgrades at new units and plans to increase capex to ~INR11b in 2HFY26 to accelerate both brownfield and greenfield capacity addition.
- It aims to double its bed capacity in the next 4-5 years through a combination of greenfield and brownfield expansions, M&A, and 'built-to-suit' lease models.
- We expect MAXH to deliver 14% revenue CAGR over FY25-28 to INR133b.


### Strong performance in Max@lab and Max@home continues

- Max@lab sustained its growth trajectory with 17% YoY expansion in 1HFY26, following 18% YoY growth in 1QFY26 and 22% YoY growth in FY25.
- In 1HFY26, EBITDA rose 11% YoY to INR140m, with EBITDA margin of 13.4%.
- The business has a strong network of 580+ collection points, 780+ pickup points, and 47 test-processing labs, with operations across 60+ cities as of Sep'25.
- We expect Max@lab to deliver a 24% revenue CAGR over FY25-28 to INR3.3b.
- Max@home delivered 21% YoY revenue growth in 1HFY26 to INR630m at the gross level, aided by physio & rehab, critical care, medicine delivery, and medical room services; repeat transactional patients now account for 60%+ over the past year.
- The segment currently operates in 15 cities, offering 15 specialized services through ~130 medical rooms and a team of ~1,500, and is expected to post a 22% revenue CAGR over FY25-28.

### Maintain BUY


- We largely maintain our estimates for FY26/FY27/FY28. We continue to value MAXH on an SoTP basis (premised on 35x 12M forward EV/EBITDA for the Hospital business, 30x 12M forward EV/EBITDA for Max@lab, and 11x EV/sales for Max@home) to arrive at a TP of INR1,360.
- MAXH continues to implement efforts for sustainable growth in revenue/EBITDA/PAT, supported by bed additions (1,300 in FY26 and ~500 in FY27). In fact, the land bank available with MAXH would enable bed additions on the brownfield basis for the next 5-7 years. It continues to optimize case mix/payor mix to further improve profitability. Maintain BUY.

**Exhibit 4: P/E Chart**



Source: MOFSL, Company, Bloomberg


**Exhibit 5: EV/EBITDA Chart**



Source: MOFSL, Company, Bloomberg


## Story in charts

**Exhibit 6: Expect 4% CAGR in ARPOB over FY25-28**




Source: MOFSL, Company

**Exhibit 7: Occupancy may decline amid capacity expansion**




Source: MOFSL, Company

**Exhibit 8: Network revenue to post 18% CAGR over FY25-28**




Source: MOFSL, Company

**Exhibit 9: Expect EBITDA margin to expand ~20bp to 26.7%**




Source: MOFSL, Company

**Exhibit 10: EPS to clock 20% CAGR over FY25-28**



Source: MOFSL, Company

**Exhibit 11: Expect RoE to be in range of 16-18%**



Source: MOFSL, Company

## Financials and valuations

### Consolidated - Income Statement

(INR m)

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Total Income from Operations</b>	<b>51,710</b>	<b>58,750</b>	<b>68,150</b>	<b>86,210</b>	<b>1,06,347</b>	<b>1,25,888</b>	<b>1,40,045</b>
Change (%)	43.6	13.6	16.0	26.5	23.4	18.4	11.2
<b>Total Expenditure</b>	<b>38,270</b>	<b>42,680</b>	<b>49,420</b>	<b>63,360</b>	<b>78,351</b>	<b>92,402</b>	<b>1,02,653</b>
% of Sales	74.0	72.6	72.5	73.5	73.7	73.4	73.3
<b>EBITDA</b>	<b>13,440</b>	<b>16,070</b>	<b>18,730</b>	<b>22,850</b>	<b>27,996</b>	<b>33,486</b>	<b>37,392</b>
Margin (%)	26.0	27.4	27.5	26.5	26.3	26.6	26.7
Depreciation	2,480	2,600	2,840	4,070	4,944	5,183	6,448
<b>EBIT</b>	<b>10,960</b>	<b>13,470</b>	<b>15,890</b>	<b>18,780</b>	<b>23,052</b>	<b>28,303</b>	<b>30,944</b>
Int. and Finance Charges	1,120	390	-380	840	1,620	1,316	1,196
Other Income	470	290	350	450	410	818	910
<b>PBT bef. EO Exp.</b>	<b>10,310</b>	<b>13,370</b>	<b>16,620</b>	<b>18,390</b>	<b>21,843</b>	<b>27,806</b>	<b>30,659</b>
EO Items	-500	-390	-670	1,640	-510	0	0
<b>PBT after EO Exp.</b>	<b>9,810</b>	<b>12,980</b>	<b>15,950</b>	<b>16,750</b>	<b>21,333</b>	<b>27,806</b>	<b>30,659</b>
Total Tax	1,430	-300	3,160	3,400	2,742	4,866	5,519
Tax Rate (%)	14.6	-2.3	19.8	20.3	12.9	17.5	18.0
Minority Interest	0	0	0	0	0	0	0
<b>Reported PAT</b>	<b>8,380</b>	<b>13,280</b>	<b>12,790</b>	<b>13,350</b>	<b>18,591</b>	<b>22,940</b>	<b>25,140</b>
<b>Adjusted PAT</b>	<b>8,807</b>	<b>11,226</b>	<b>13,316</b>	<b>14,672</b>	<b>17,553</b>	<b>22,940</b>	<b>25,140</b>
Change (%)	401.8	27.5	18.6	10.2	19.6	30.7	9.6
Margin (%)	17.0	19.1	19.5	17.0	16.5	18.2	18.0

### Consolidated - Balance Sheet

(INR m)

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	9,696	9,696	9,696	9,696	9,696	9,696	9,696
Total Reserves	57,484	71,004	83,254	95,634	1,12,286	1,33,287	1,58,427
<b>Net Worth</b>	<b>67,180</b>	<b>80,700</b>	<b>92,950</b>	<b>1,05,330</b>	<b>1,21,982</b>	<b>1,42,983</b>	<b>1,68,123</b>
Minority Interest	0	0	0	0	0	0	0
Total Loans	9,180	6,820	11,770	24,920	23,920	23,920	23,920
Deferred Tax Liabilities	1,850	-500	370	1,510	1,510	1,510	1,510
<b>Capital Employed</b>	<b>78,210</b>	<b>87,020</b>	<b>1,05,090</b>	<b>1,31,760</b>	<b>1,47,412</b>	<b>1,68,413</b>	<b>1,93,553</b>
Gross Block	37,100	39,210	57,290	78,920	97,256	1,14,973	1,31,567
Less: Accum. Deprn.	2,480	2,600	5,440	9,510	14,454	19,636	26,084
<b>Net Fixed Assets</b>	<b>34,620</b>	<b>36,610</b>	<b>51,850</b>	<b>69,410</b>	<b>82,802</b>	<b>95,337</b>	<b>1,05,483</b>
Goodwill on Consolidation	37,730	37,730	42,670	47,950	47,950	47,950	47,950
Intangibles	6,880	6,810	7,370	6,980	6,980	6,980	6,980
Capital WIP	0	0	7,620	12,920	10,584	11,367	9,773
<b>Total Investments</b>	<b>20</b>	<b>20</b>	<b>660</b>	<b>40</b>	<b>40</b>	<b>40</b>	<b>40</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>17,192</b>	<b>22,997</b>	<b>20,776</b>	<b>25,870</b>	<b>30,258</b>	<b>43,623</b>	<b>64,338</b>
Inventory	830	1,040	1,060	1,340	1,909	2,252	2,501
Account Receivables	4,533	4,340	6,000	8,570	9,324	11,037	12,278
Cash and Bank Balance	6,150	15,650	12,860	10,110	11,581	21,523	39,755
Loans and Advances	5,679	1,967	856	5,850	7,444	8,812	9,803
<b>Curr. Liability &amp; Prov.</b>	<b>18,233</b>	<b>17,147</b>	<b>25,856</b>	<b>31,410</b>	<b>31,203</b>	<b>36,884</b>	<b>41,011</b>
Account Payables	5,667	6,438	10,170	14,350	11,819	13,939	15,485
Other Current Liabilities	8,369	5,940	10,155	10,660	10,752	12,728	14,159
Provisions	4,197	4,768	5,531	6,400	8,631	10,217	11,366
<b>Net Current Assets</b>	<b>-1,040</b>	<b>5,850</b>	<b>-5,080</b>	<b>-5,540</b>	<b>-945</b>	<b>6,739</b>	<b>23,327</b>
<b>Appl. of Funds</b>	<b>78,210</b>	<b>87,020</b>	<b>1,05,090</b>	<b>1,31,760</b>	<b>1,47,412</b>	<b>1,68,413</b>	<b>1,93,553</b>

E: MOSL Estimates



## Financials and valuations

### Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Basic (INR)</b>							
<b>Adj. EPS</b>	<b>9.1</b>	<b>11.6</b>	<b>13.7</b>	<b>15.1</b>	<b>19.6</b>	<b>23.7</b>	<b>25.9</b>
Cash EPS	11.6	14.3	16.7	19.3	24.7	29.0	32.6
BV/Share	69.3	83.2	95.9	108.7	125.8	147.5	173.4
DPS	0.0	0.0	0.0	1.5	2.0	2.0	0.0
Payout (%)	0.0	0.0	0.0	10.9	10.4	8.5	0.0
<b>Valuation (x)</b>							
P/E	125.5	98.4	83.0	75.4	58.1	48.2	44.0
Cash P/E	97.9	79.9	68.4	59.0	46.1	39.3	35.0
P/BV	16.4	13.7	11.9	10.5	9.1	7.7	6.6
EV/Sales	21.4	18.7	16.2	13.0	10.5	8.8	7.8
EV/EBITDA	82.4	68.2	58.9	49.0	39.9	33.1	29.1
Dividend Yield (%)	0.0	0.0	0.0	0.1	0.2	0.2	0.0
FCF per share	4.4	17.8	-3.3	-11.4	5.8	12.8	19.1
<b>Return Ratios (%)</b>							
RoE	14.1	15.2	15.3	14.8	16.7	17.3	16.2
RoCE	13.5	17.2	13.5	13.0	14.8	15.4	14.6
RoIC	13.8	19.2	16.4	15.5	17.2	17.9	18.2
<b>Working Capital Ratios</b>							
Fixed Asset Turnover (x)	1.4	1.5	1.2	1.1	1.1	1.1	1.1
Asset Turnover (x)	0.7	0.7	0.6	0.7	0.7	0.7	0.7
Inventory (Days)	6	6	6	6	7	7	7
Debtor (Days)	32	27	32	36	32	32	32
Creditor (Days)	40	40	54	61	41	40	40
<b>Leverage Ratio (x)</b>							
Current Ratio	0.9	1.3	0.8	0.8	1.0	1.2	1.6
Interest Cover Ratio	9.8	34.5	-41.8	22.4	14.2	21.5	25.9
Net Debt/Equity	0.0	-0.1	0.0	0.1	0.1	0.0	-0.1

### Consolidated - Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>(INR m)</b>							
OP/(Loss) before Tax	10,310	13,370	15,950	16,750	21,333	27,806	30,659
Depreciation	2,480	2,600	2,840	4,070	4,944	5,183	6,448
Interest & Finance Charges	1,120	390	-730	390	1,210	497	286
Direct Taxes Paid	-1,430	300	-3,160	-3,400	-2,742	-4,866	-5,519
(Inc)/Dec in WC	-1,300	2,609	8,141	-2,290	-3,124	2,258	1,645
<b>CF from Operations</b>	<b>11,180</b>	<b>19,269</b>	<b>23,041</b>	<b>15,520</b>	<b>21,620</b>	<b>30,878</b>	<b>33,518</b>
<b>CF from Operating incl EO</b>	<b>11,180</b>	<b>19,269</b>	<b>23,041</b>	<b>15,520</b>	<b>21,620</b>	<b>30,878</b>	<b>33,518</b>
(Inc)/Dec in FA	-6,880	-1,990	-26,260	-26,540	-16,000	-18,500	-15,000
<b>Free Cash Flow</b>	<b>4,300</b>	<b>17,279</b>	<b>-3,219</b>	<b>-11,020</b>	<b>5,620</b>	<b>12,378</b>	<b>18,518</b>
(Pur)/Sale of Investments	0	0	-640	620	0	0	0
Others	470	290	350	-4,830	410	818	910
<b>CF from Investments</b>	<b>-6,410</b>	<b>-1,700</b>	<b>-26,550</b>	<b>-30,750</b>	<b>-15,590</b>	<b>-17,682</b>	<b>-14,090</b>
Issue of Shares	37	0	0	0	0	0	0
Inc/(Dec) in Debt	-2,100	-2,360	4,950	13,150	-1,000	0	0
Interest Paid	-1,120	-390	380	-840	-1,620	-1,316	-1,196
Dividend Paid	0	0	0	0	-1,939	-1,939	0
Others	0	0	0	170	0	0	0
<b>CF from Fin. Activity</b>	<b>-3,183</b>	<b>-2,750</b>	<b>5,330</b>	<b>12,480</b>	<b>-4,559</b>	<b>-3,254</b>	<b>-1,196</b>
<b>Inc/Dec of Cash</b>	<b>1,587</b>	<b>14,819</b>	<b>1,821</b>	<b>-2,750</b>	<b>1,471</b>	<b>9,942</b>	<b>18,232</b>
Opening Balance	6,660	6,150	15,650	12,860	10,110	11,581	21,523
<b>Closing Balance</b>	<b>6,150</b>	<b>15,650</b>	<b>12,860</b>	<b>10,110</b>	<b>11,581</b>	<b>21,523</b>	<b>39,755</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.



Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on [www.motilaloswal.com](http://www.motilaloswal.com) > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.